Advertisement

PharmacoEconomics

, Volume 35, Issue 10, pp 977–980 | Cite as

ICER’s Revised Value Assessment Framework for 2017–2019: A Critique

  • Peter J. NeumannEmail author
  • Joshua T. Cohen
Commentary

Introduction

Given the ever-growing visibility of its evidence reports and the alarm bells they have triggered in C-suites of pharmaceutical companies, it is sometimes easy to forget that the Institute for Clinical and Economic Review (ICER) is a private, non-profit organization in the USA with no regulatory or reimbursement authority. However, ICER has evolved to be a group to be reckoned with, issuing report after report on the value of drugs and other technologies. Thus, its recently released update to its value assessment framework that will govern the organization’s evaluations through mid-2019 warrants close attention [1].

ICER’s legitimacy stems not from statutory authority or public subsidies, but from the fact that it has surfaced as a credible response to demand among US private payers for health technology assessment (HTA) to counter high drug (and device) prices. Indeed, ICER has filled a vacuum created by the absence of US Government entities in the space.

ICER has emerged...

Notes

Compliance with Ethical Standards

Funding

No funding was received for this commentary.

Conflicts of interest

The Center for the Evaluation of Value and Risk in Health at Tufts Medical Center receives funding from numerous government, non-profit foundation, and pharmaceutical industry sources. Both Drs Neumann and Cohen have frequently consulted with the pharmaceutical industry and serve as consultants to Precision Health Economics.

References

  1. 1.
    Institute for Clinical and Economic Review. Overview of the ICER assessment framework and update for 2017–2019. https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-update-FINAL-062217.pdf. Accessed 24 Jul 2017.
  2. 2.
    Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.Google Scholar
  3. 3.
    Lakdawalla D, Neumann PJ. Budget criteria and drug value assessments: a case of apples and oranges? Health Affairs Blog. 22 Sep 2015. http://healthaffairs.org/blog/2016/09/22/budget-criteria-and-drug-value-assessments-a-case-of-apples-and-oranges/. Accessed 24 Jul 2017.
  4. 4.
    Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015;373:2595–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy StudiesTufts Medical CenterBostonUSA

Personalised recommendations